TITLE

Osteoporosis and fluoride therapy

PUB. DATE
September 1970
SOURCE
British Medical Journal;9/19/1970, Vol. 3 Issue 5724, p660
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
64098024

 

Related Articles

  • Fluoride therapy for the vertebral crush fracture syndrome. A status report. Heaney, Robert P.; Baylink, David J.; Johnston Jr., C. Conrad; Melton III, L. Joseph; Meunier, Pierre J.; Murray, TimothyM.; de Deuxchaisnes, Charles Nagant; Heaney, R P; Baylink, D J; Johnston, C C Jr; Melton, L J 3rd; Meunier, P J; Murray, T M; Nagant de Deuxchaisnes, C // Annals of Internal Medicine;10/15/89, Vol. 111 Issue 8, p678 

    Emphasizes the efficacy and safety of fluoride therapy for vertebral crush fracture syndrome. Effects of sodium fluoride therapy on bone in patients with osteoporosis; Guidelines for fluoride therapy; Side effects of fluoride therapy.

  • Geriatric Medicine. Larson, Eric B. // JAMA: Journal of the American Medical Association;6/19/91, Vol. 265 Issue 23, p3125 

    Focuses on geriatric medicine. Factors that contribute to patient well-being; Maintenance of the integrity of the muscoskeletal system; Fluoride therapy for osteoporosis.

  • Bring back bone.  // Prevention;Sep94, Vol. 46 Issue 9, p49 

    Cites research on a promising therapy using fluoride that may reverse osteoporosis. Report in `Annals of Internal Medicine,' April 15, 1994; Researcher Khashayar Sakhaee, MD.

  • Fluoride Treatment of Osteoporosis: A New Look at an Old Drug. Bikle, Daniel D. // Annals of Internal Medicine;Jun83, Vol. 98 Issue 6, p1013 

    Editorial. Discusses the therapeutic use of fluoride for osteoporosis. Role of fluoride in bone growth; Information on osteoporosis; Evidence on the therapeutic potential of fluoride for osteoporosis.

  • Salmon Calcitonin in the Treatment of Postmenopausal Osteoporosis.  // Annals of Internal Medicine;Dec87, Vol. 107 Issue 6, p923 

    Editorial. Deals with the efficacy of the use of salmon calcitonin for the treatment of postmenopausal osteoporosis, which is approved by the Food and Drug Administration besides the use of estrogen. Concern raised in the use of estrogen therapy; Function of sodium fluoride therapy;...

  • Osteoporosis Prevention and Treatment. Bellantoni, Michele F. // American Family Physician;9/1/1996, Vol. 54 Issue 3, p986 

    Discusses the prevention and treatment of osteoporosis. Hormone therapies; Calcium and vitamin D; Exercise and behavior factors; Biochemical markers for evaluation; Radiologic techniques; Biphosphonates, calcitonin and fluoride as treatment options.

  • Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Ringe, J.D.; Rovati, L.C. // Calcified Tissue International;Oct2001, Vol. 69 Issue 4, p252 

    Alendronate has been approved as a first antiresorptive drug for treatment of osteoporosis in men. Except for fluoride, in some countries so far there has been no approved anabolic substance for the treatment of male osteoporosis. From small studies in men and male patients included in studies...

  • Letter. Reginster, J-y; Rovati, Lucio C.; Setnikar I I, Ivo // Osteoporosis International;Sep2001, Vol. 12 Issue 9, p800 

    Presents a letter to the editor of the periodical "Osteoporosis International" concerning a regimen of fluoride and calcium for reducing the risk of vertebral fractures in postmenopausal osteoporosis.

  • Giant Cells in Bone Marrows of Patients oh High--Dose Fluoride Treatment. Duffey, Paul H.; Tretbar, Harold C.; Jarkowski, Thaddeus L. // Annals of Internal Medicine;Nov71, Vol. 75 Issue 5, p745 

    Describes the case of several patients who have undergone experimental sodium fluoride (NaF) therapy for osteoporosis and were diagnosed of having giant cells in their bone marrows. Information on NaF therapy; Description of the giant monocytoid cells that have been found from the patients;...

  • Proposed Fluoride Ban in Belgium. Segreti, Sarah // Positive Health;Mar2003, Issue 86, p7 

    Cites the proposed ban on fluoride in Belgium. Concern over the increased risk for osteoporosis of the overuse of fluoride substances; Commercial products affected by the ban.

Share

Other Topics